Education
About Us
Working with TipRanks
Follow Us
Adicet Bio (ACET)
NASDAQ:ACET
ACET Stock Chart & Stats
$7.03
-$0.04(-4.07%)
At close: 4:00 PM EST
$7.03
-$0.04(-4.07%)
Day’s Range― - ―
52-Week Range$6.41 - $17.43
Previous CloseN/A
Volume197.46K
Average Volume (3M)1.92M
Market Cap
$67.34M
Enterprise Value$53.77M
Total Cash (Recent Filing)$103.10M
Total Debt (Recent Filing)$15.54M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Mar 05, 2026EPS Estimate
-2.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.64
Shares Outstanding9,578,474
10 Day Avg. Volume4,877,229
30 Day Avg. Volume1,918,806
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.90
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.50
Forecast
1Y Price Target
$29.33Price Target Upside317.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy In Lupus NephritisEarly clinical results showed strong and durable renal responses in lupus nephritis patients treated with the company's CD20-targeting cell therapy, supporting the therapy's potential to deliver meaningful clinical benefit.
Regulatory Pathway And Pivotal Trial ProgressPlanned engagement with the FDA and intent to initiate a pivotal lupus nephritis trial that aims to align with peer program designs could clarify approval requirements and materially de-risk development if favorable results are achieved.
Safety Profile And Treatment UsabilityReported tolerability with no serious immune-related toxicities and the ability for patients to stop immunosuppressants and taper steroids suggests potential for outpatient dosing and broader clinical adoption.
Bears Say
Analyst Valuation ConservatismSome analysts lowered success assumptions and increased discounting of future cash flows to reflect higher perceived program risk, which could exert downward pressure on sentiment and the stock's valuation.
Listing Pressure And Capital-structure ChangesImplementation of a reverse stock split to maintain exchange listing altered the capital structure and signals listing pressure, which may raise investor concerns about liquidity and marketability.
Share Dilution And Valuation ImpactA large share issuance produced material dilution that reduced existing shareholder ownership and prompted a reassessment of the company's valuation.
Adicet Bio News
ACET FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest stock price was $6.41 and its highest was $17.43 in the past 12 months.
What is Adicet Bio’s market cap?
Adicet Bio’s market cap is $67.34M.
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is Mar 05, 2026 which is in 24 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on Nov 05, 2025. The company reported -$4.64 earnings per share for the quarter, missing the consensus estimate of -$4.639 by >-$0.001.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio pays a Quarterly dividend of $0.01 which represents an annual dividend yield of N/A. See more information on Adicet Bio dividends here
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -2.91.
How many shares outstanding does Adicet Bio have?
Adicet Bio has 9,578,474 shares outstanding.
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -$4.64 in its last earnings report, missing expectations of -$4.639. Following the earnings report the stock price went down -1.92%.
Which hedge fund is a major shareholder of Adicet Bio?
Currently, no hedge funds are holding shares in ACET
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adicet Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.33 (317.21% Upside)
$29.33 (317.21% Upside)
Hedge Fund Trend
Decreased
By 109.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 15.9%
Last 30 Days ▼ 15.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.86%
12-Months-Change
Fundamentals
Return on Equity
-71.73%
Trailing 12-Months
Asset Growth
-39.38%
Trailing 12-Months
Company Description
Adicet Bio
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
ACET Stock 12 Month Forecast
Average Price Target
$29.33
▲(317.21% Upside)
Technical Analysis
Sutro Biopharma
―
PMV Pharmaceuticals
―
Gain Therapeutics
―
Immix Biopharma
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
Currently, No data available
---